A Phase 3 interventional study of Esomeprazole 20 mg in Gastric Ulcer, Duodenal Ulcer and Rheumatoid Arthritis, sponsored by AstraZeneca. Completed at 3 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2012-09-14.
Sponsored by AstraZeneca · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing esomeprazole in Stomach Ulcer — none open to participants now, none under way, none of them phase 3. Esomeprazole · Stomach Ulcer.
Among the 11 studies testing esomeprazole in Stomach Ulcer, this one is the 8th largest by enrollment, is one of 3 that started in 2007, is one of 9 in phase 3, and was the 5th registered.
116 studies on the registry are indexed under Stomach Ulcer; 13 are open to participants now.
Browse Stomach Ulcer studies →None of the 11 studies testing esomeprazole in Stomach Ulcer is open now. The open studies under Stomach Ulcer, anywhere →
Esomeprazole: first FDA approval 2001 (NEXIUM), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 10 Stomach Ulcer studies recruiting now, 6 (60%) set no upper age limit and 3 (30%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 3 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 395 is above the median of 298 across 88 interventional studies indexed under Stomach Ulcer.
Median enrollment 400 across the 11 interventional studies. Of the 11 that completed or were terminated, 6 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 11 have an industry lead sponsor. The 2 most frequent:
AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
17 studies in Stomach Ulcer by AstraZeneca: none open now, none under way, none of them phase 3. Of 17 finished, 7 (41%) have results posted.
Among the 17 studies in Stomach Ulcer by AstraZeneca, this one is the 8th largest by enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2007, is one of 11 in phase 3, and was the 5th registered.
AstraZeneca’s Stomach Ulcer studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing esomeprazole in Stomach Ulcer, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 17 in Stomach Ulcer:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the Safety and tolerability of D961H (Esomeprazole) 20 mg once daily for up to 52 weeks of treatment involving patients with a history of gastric and/or duodenal ulcers receiving daily nonsteroidal anti-inflammatory drug (NSAID) therapy by evaluating AE, clinical laboratory value and vital signs.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Esomeprazole 20 mg once daily
Drug: Esomeprazole 20 mg
Esomeprazole 20 mg once daily
Number of Participants Without Gastric and/or Duodenal Ulcer Throughout the Treatment Period
Time frame: up to 52 weeks
Number of Participants Without Gastric and/or Duodenal Ulcer up to 4 Weeks After Treatment
Time frame: up to 4 weeks after treatment
Number of Participants Without Gastric and/or Duodenal Ulcer up to 12 Weeks After Treatment
Time frame: up to 12 weeks after treatment
Number of Participants Without Gastric and/or Duodenal Ulcer up to 24 Weeks After Treatment
Time frame: up to 24 weeks after treatment
First participant enrolled 2 Oct 07. Last completed 8 Sept 09. 395 enrolled, 130 registered in study. All registered were included in Full Analysis set and safety analysis set. FAS used for summaries of baseline characteristics and efficacy, safety analysis set for summaries of safety variables.
| Milestone | Esomeprazole 20mg |
|---|---|
| Started | 130 |
| Completed | 111 |
| Not completed | 19 |
| Withdrew: Adverse event | 6 |
| Withdrew: Withdrawal by subject | 4 |
| Withdrew: Protocol violation | 2 |
| Withdrew: Recurrence of ulcer | 5 |
| Withdrew: Usage of prohibited treatment | 1 |
| Withdrew: No intention to attend regularly | 1 |
| Participants | Esomeprazole 20mg |
|---|---|
| Number of Participants Without Gastric and/or Duodenal Ulcer up to 4 Weeks After Treatment | 130 (NA to NA) |
| participants | Esomeprazole 20mg |
|---|---|
| Number of Participants Without Gastric and/or Duodenal Ulcer up to 12 Weeks After Treatment | 127 (NA to NA) |
| participants | Esomeprazole 20mg |
|---|---|
| Number of Participants Without Gastric and/or Duodenal Ulcer up to 24 Weeks After Treatment | 126 (NA to NA) |
| Participants | Esomeprazole 20mg |
|---|---|
| Number of Participants Without Gastric and/or Duodenal Ulcer Throughout the Treatment Period | 125 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Esomeprazole 20mg | — | 14/130 (10.8%) | 123/130 (94.6%) |
| Event | Esomeprazole 20mg |
|---|---|
| Rheumatoid Arthritis AggravatedMusculoskeletal and connective tissue disorders | 3/130 |
| Osteoarthritis DeteriorationMusculoskeletal and connective tissue disorders | 2/130 |
| PyelonephritisInfections and infestations | 2/130 |
| Pain In ExtremityMusculoskeletal and connective tissue disorders | 1/130 |
| SpondylolisthesisMusculoskeletal and connective tissue disorders | 1/130 |
| ErysipelasInfections and infestations | 1/130 |
| InfluenzaInfections and infestations | 1/130 |
| PneumoniaInfections and infestations | 1/130 |
| SepsisInfections and infestations | 1/130 |
| Campylobacter Intestinal InfectionInfections and infestations | 1/130 |
| Event | Esomeprazole 20mg |
|---|---|
| NasopharyngitisInfections and infestations | 38/130 |
| Rheumatoid ArthritisMusculoskeletal and connective tissue disorders | 17/130 |
| Abdominal Pain UpperGastrointestinal disorders | 14/130 |
| ConstipationGastrointestinal disorders | 12/130 |
| DiarrhoeaGastrointestinal disorders | 11/130 |
| Stomach DiscomfortGastrointestinal disorders | 10/130 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 9/130 |
| NauseaGastrointestinal disorders | 8/130 |
| HeadacheNervous system disorders | 8/130 |
| StomatitisGastrointestinal disorders | 7/130 |
| Age, Customized(Participants) | Esomeprazole 20mg |
|---|---|
| < 65 years | 63 (63 to NA) |
| 65 - 74 years | 43 (43 to NA) |
| >= 75 years | 24 (24 to NA) |
| Sex/Gender, Customized(Participants) | Esomeprazole 20mg |
|---|---|
| Male | 35 (35 to NA) |
| Female | 95 (95 to NA) |
The record gives a start of Oct 2007, a primary completion of Sep 2009 and a completion of Sep 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2012, 3 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Esomeprazole